Urine BETA CrossLaps® (CTX-I) ELISA
Product Description
For determination of degradation products of C-terminal telopeptides of Type I collagen (CTX-I) in human urine. CTX-I can be used as an indicator of bone resorption status.
- Supports the management of postmenopausal osteoporosis and prediction of long-term skeletal response to anti-resorptive therapies, e.g. HRT, bisphosphonates – Encourages patient motivation and compliance
- Allows the assessment of bone resorption in patients with metabolic bone disease, e.g. hyperparathyroidism, Paget´s disease, osteodystrophy and those receiving prolonged glucocorticoid therapy
- CTX-I is considered a reference marker for osteoporosis management as indicated by IOF, IFCC and NBHA
- Easy to perform – one step incubation
- Excellent correlation with automated methods
- Part of a complete assay panel supporting bone disease management
Results are to be used in conjunction with other clinical and laboratory data as an aid in:
- Monitoring bone resorption changes of anti-resorptive therapies (such as hormone replacement therapies (HRT) with hormones or hormone like drugs and bisphosphonate therapies) in postmenopausal women and individuals diagnosed with osteopenia
- Predicting skeletal response (Bone Mineral Density) in postmenopausal women undergoing anti resorptive therapies, such as HRT with hormones or hormone like drugs and bisphosphonate therapies.
-
- Bjarnason NH & Christiansen C. Early Response in Biochemical Markers Predicts Long-term Response in Bone Mass During Hormone Replacement Therapy in Early Postmenopausal Women. Elsevier 26; 561-569 (2000).
- Bonde M, Garnero P, Fledelius C, et al. Measurement of bone degradation products in serum using antibodies reactive with an isomerized from of an 8 amino acid sequence of the C-telopeptide of Type I collagen. J Bone Miner Res 12:1028-1034 (1997).
- Bonde M, Qvist P, Fledelius C, et al. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps®) -follow up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol & Metab 80:864-8 (1995).
- Buclin T, Rochat MC, Burckhardt P, et al. Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J Bone Miner Res 17;8-1478 (2002).
- Burgeson RE. New collagens, new concepts. Annu Rev Cell Biol 4:551-77 (1988).
- Vasikaran SD et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2010; 22(2):391-420.
- Product Code: AC-05F1
- Number of Tests: 96 wells
- Sample Type: Urine
- Sample Volume: 20 µL
- Assay Range: 0 – 30 µg/L
- Add to Enquiry Basket
Interested? Enquire now.
Add to Enquiry Basket
Related Products
| Assays | Certification | Platform | Clinical Area | Portfolio | RUO/IVD |
|---|---|---|---|---|---|
| Serum Crosslaps® (CTX-I) ELISA | 510 (k) exemptCE Marked | Bone TurnoverBone Turnover Markers | Animal ResearchEndocrinology | IVD | |
| N-MID® Osteocalcin | CE Marked | i10iSYS | Bone Turnover | Endocrinology | IVD |
| Ostase® BAP | CE MarkedFDA Cleared | i10iSYS | Bone TurnoverCKD-MBD | Endocrinology | IVD |
| Urine CrossLaps® (CTX-I) EIA | 510 (k) exemptCE Marked | Bone TurnoverBone Turnover Markers | Animal ResearchEndocrinology | IVD | |
| BoneTRAP® (TRAcP 5b) ELISA | CE Marked | Bone TurnoverBone Turnover Markers | Animal ResearchEndocrinology | IVD | |
| Alpha CrossLaps® (CTX-I) EIA | 510 (k) exemptCE Marked | Bone TurnoverBone Turnover Markers | Animal ResearchEndocrinology | IVD |